CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Inc. [NASDAQ:ARIA]

Nicholas Ventresca, SVP & CIO, ARIAD Pharmaceuticals

How to Nurture a Biotech? Sometimes, Like a Teenager

Nicholas Ventresca

We are at a point in time where the old perceptions of what a biotech company is and is not are beginning to exceed the rules. Where we had once thought of biotechs as needing less Information Technology solutions in comparison to big pharma, we are now realizing that isn’t necessarily the case. Biotechs can oftentimes be compared to teenagers—facing maturity issues that come with major changes like launching a first commercial medicine—all under the watchful eyes of worldwide regulatory agencies, the SEC and investors, and while maintaining the youthful scientific environment that made it great to begin with.


It is the CIO’s job to maintain an environment where a biotech can continue rapid growth, where employees can be empowered to work on medicines that help patients, and to do so in accordance with a myriad of regulations. The pace is similar to the rapid technology changes we see every day. The “Consumerization of IT,” when well used, is incredible for collaboration and using your own devices. However, like a teenager with the latest social app on their phone, the communication is great, yet you always have to be careful of what you’re posting, since it stays there forever. These rapidly evolving technologies are often introduced early in a biotech. When used appropriately, they enable the people who dedicate their brilliance to changing patient lives for the better to make faster decisions and collaborate easily.


When I joined ARIAD in March 2015, one of my first responsibilities was to develop a series of roadmaps to ensure that team members in each division of the company had ready access to the appropriate IT solutions to support their needs. With this effort, we had to identify and implement internal systems that would connect our researchers with each other and to ensure our teams in various areas— including discovery, clinical, medical affairs, regulatory, pharmacovigilance, marketing and sales—have secure access to their data and information. We spent a good amount of time researching, assessing and choosing the best systems available to meet our needs while retaining the flexibility to expand and update those technologies as needed during periods of rapid growth or the launch of new research and development platforms.


Leaders in Information Technology are the stewards of information along what we call the “information pipeline.” If you are in biotech, you need to understand information-transfer needs of all of the internal groups at the company as well as what can be shared (by law) with physicians and patients. Prior to dedicating my career to Information Technology, I had an education and experience in biology and medicine. This background, while not essential, has helped me to understand the work and technology needs of our researchers and scientists. Relevant experience in biotechnology or pharmaceutical companies can provide much of the same insight to IT professionals.


IT teams in biotech are certainly driven by a sense of a greater good and a willingness to be accountable and helpful whenever needed


My overall responsibility of streamlining information sharing has to be balanced with a high level of accountability to protect the data between divisions so that the right information is available to the right minds…kind of like a teenager, needing to know just enough about the world, delivered in an understandable context.


Like many innovative biotechnology companies, we have a dynamic workforce that is generally comfortable with new technologies. They depend upon our decisions in IT to support their ability to work remotely, transfer information securely, and participate in all forms of online and electronic communication. They need to be assured of the necessary levels of protection both on- and off-site. In IT we need to stay on top of both risks to security and new options to improve security. For example, while we have found that having employees provide two-factor authentication when logging into our systems has worked well, it also can be cumbersome. We are considering adopting more advanced technologies such as facial recognition software for some applications to make connecting with information more seamless. The “cool factor” is evident in biotechs, but needs to be appropriately balanced. Again, kind of like those teenage years.


One of the things I love about working in IT in a biotech is that we get to work at every level in the company and collaborate with company leadership to identify and assess new technologies and strategies. There is nothing like hearing from patients who have come into our building to share their experiences with our medicine. IT teams in biotech are certainly driven by a sense of a greater good and a willingness to be accountable and helpful whenever needed. The whole firm is affected by personal accounts of patients we are treating.


For those of you considering a future in biotech IT, there is really nothing like the pace, the challenges and personal satisfaction. I will never forget meeting one patient in particular, a father who was on our medicine and who also had a background in Information Technology. It drove home that we are developing medicines for people who could be our friends and colleagues. While it was interesting to share perspectives about technology, seeing the impact of our work first-hand just cannot be compared.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/cioviewpoint/how-to-nurture-a-biotech-sometimes-like-a-teenager-nwid-280.html